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Purpose: Triple negative breast cancer (TNBC) constitutes 10-15% of female breast cancers, and clinical guidelines
recommend treatment with chemotherapy and surgery. We examined the recorded treatment and survival of
women with TNBC in a population-based sample within the UK.
Methods: Cancer registration data for North East London women diagnosed between 2005 and 2007 were
supplemented with pathology data on hormone receptor status to determine triple negative status. Receipt of
surgery, chemotherapy, radiotherapy, hormone therapy, or surgery plus chemotherapy according to TNBC status
was assessed using logistic regression, and adjusted for age, stage of disease and socioeconomic deprivation.
Five-year survival according to TNBC status and treatment was estimated using the Kaplan-Meier method and Cox
regression analysis examined adjusted all-cause mortality.
Results: Triple negative status could be determined for 1228 of 2394 women with breast cancer and 128 (10%) had
TNBC. Compared to patients without TNBC, patients with TNBC were more likely to receive chemotherapy (fully
adjusted odds ratio (OR) =4.21, 95% confidence interval (CI) 2.63-6.75) or surgery plus chemotherapy (fully adjusted
OR = 2.52, 95% CI 1.61-3.93). Of patients with TNBC, those who received surgery plus chemotherapy had the
greatest 5-year survival estimate (0.74, 95% CI 0.60-0.83). Overall, patients with TNBC had a higher risk of death
(fully adjusted hazard ratio (HR) =1.69, 95% CI 1.24-2.30) compared to those without TNBC.
Conclusions: This population-based study found that despite women with TNBC being more likely to receive
chemotherapy, or surgery plus chemotherapy, they had a poorer overall survival than with those without TNBC.
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Breast cancer is the most common type of cancer diag-
nosed amongst women in the UK, accounting for 30% of
all new cancer cases in women in 2011 (Cancer Research
UK). It is increasingly understood as a heterogeneous
disease (Metzger-Filho et al. 2012), and one specific sub-
type of breast cancer that is receiving particular atten-
tion is triple negative breast cancer (TNBC). TNBC is
defined as a breast cancer that is oestrogen receptor
(ER) negative, progesterone receptor (PR) negative and
lacks expression of HER-2. This cancer subtype is esti-
mated to account for 10-15% of all breast cancer diagnoses* Correspondence: shrestha.pal@kcl.ac.uk
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in any medium, provided the original work is p(Dawood 2010), and is associated with poor overall sur-
vival (Oakman et al. 2010).
In England, clinical guidelines provided by the National
Institute for Health and Clinical Excellence (NICE) recom-
mend surgery and systemic therapy for the treatment of
breast cancer (National Institute for Health and Care Ex-
cellence 2010). Systemic therapy includes chemotherapy,
radiotherapy or hormone therapy, and depends on the
tumour hormone receptor status, lymph nodal involve-
ment, and risk of recurrence. Guidelines are not specific
to TNBC (National Institute for Health and Care Excel-
lence 2010), and current clinical practice is based upon
evidence from clinical trials, which show that chemother-
apy combined with surgery is the most effective treatment
for patients with TNBC (Isakoff 2010; Rodler et al. 2010;
Carey et al. 2010). NICE guidelines recommend adjuvant
treatment for early breast cancer with anthracylines and/pen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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lence 2010), and encourage the provision of radiotherapy
in early or locally invasive breast cancer (National Institute
for Health and Care Excellence 2010). Specific guidelines
for the role of radiotherapy in TNBC do not exist, so its
role is somewhat unclear.
To the best of our knowledge, there have been no
population-based studies that have compared a range of
treatments received by patients with TNBC, with those for
patients without TNBC in the UK. Studies have researched
the efficacy of particular treatment options (Isakoff 2010;
Rodler et al. 2010; Carey et al. 2010; Colleoni et al. 2010),
but none have investigated whether these treatments are
being implemented in a London population.
This study follows on from a previous population-based
analysis of the hormone receptor status of a cohort of
breast cancer patients resident in an area of North East
London (Jack et al. 2013). The previous study investigated
differences in receptor status amongst women from vari-
ous ethnic groups, and reported a greater likelihood of
TNBC in those from Black and South Asian groups (Jack
et al. 2013). Following those findings, this population-
based study aimed to compare the treatment received by
patients with and without TNBC, to assess their survival,
and whether this may be influenced by treatment or other
demographic or clinical factors.
Methods
The occurrence of cancer in the English population is
now recorded by the National Cancer Registration
Service. During the time period of the study, recording
of cancer in the London population was carried out by
the former Thames Cancer Registry (TCR). Registrations
were initiated by clinical and pathological information
received from hospitals and by information about deaths
provided by the National Health Service Central Register
through the Office for National Statistics. Trained can-
cer registration officers then extracted further informa-
tion on demographic details, disease stage and treatment
in the first six months after diagnosis from individual
medical records. Data were quality assured as they are
added to the central database.
Data on 2417 female residents of the area of North
East London covered by the former North East London
Cancer Network (NELCN) diagnosed with breast cancer
(ICD-10 C50) between 2005 and 2007 were extracted
from the registration dataset. Breast cancers identified
from a death certificate only were excluded (n = 23),
leaving a population of 2394 women. For this study, can-
cer registration data were supplemented with electronic
pathology record data received from hospitals in the
area. Information on ER, PR and HER-2 receptor sta-
tuses was used to derive triple negative disease status.
Patients were classified as having TNBC when all threehormone receptor statuses were negative, and as not hav-
ing TNBC if at least one hormone receptor was present or
borderline. Where hormone receptor statuses were a
combination of unknown and negative, or all missing,
these patients were defined to have an unknown triple
negative status.
Information about the type of treatment received
within six months (183 days) of diagnosis was identified.
The following treatments were studied: surgery, chemo-
therapy, surgery plus chemotherapy, radiotherapy, and
hormone therapy. Age was categorised into 5-year inter-
vals. Due to small numbers in the youngest and oldest
age groups, 20–29 and 75 and over age groups were cre-
ated. As TNM staging data was often incomplete within
medical records, TCR used the staging information
available to define five categories of stage of disease at
diagnosis: 1) localised tumour; 2) extension beyond the
organ of origin; 3) regional lymph node involvement;
4) metastatic disease, and 5) not known.
Socioeconomic deprivation was measured by lower
layer super output area of residence, based on the in-
come domain of the English Indices of Deprivation 2007
(Communities and Local Government 2007), and
grouped into quintiles; 1 (least deprived) to 5 (most de-
prived). Patients were assigned to a quintile of socioeco-
nomic deprivation based on their postcode of residence.
Statistical analyses
Logistic regression was used to determine the odds of
receiving each type of treatment for patients with and
without TNBC, and adjusted for age, stage and socioeco-
nomic deprivation. Five-year survival rates according to
TNBC status and treatment were estimated using the
Kaplan-Meier method. Cox proportional hazards regres-
sion analysis was used to assess all-cause mortality accord-
ing to TNBC status, adjusted for age, stage of disease,
socioeconomic deprivation, and treatment. Survival time
was calculated from the date of diagnosis until the date of
death from any cause or censored at the end of the
follow-up period, on 30th September 2012. Although all
data analyses were modelled with the ‘not known’ hor-
mone receptor status group, the main focus is on the
comparison between patients with and without TNBC.
Results
Triple negative disease status could be determined for
1228 of 2394 women diagnosed with breast cancer in the
study area of North East London during 2005 to 2007. Of
the 1228 women in whom triple negative disease status
was determined, 128 (10%) women were diagnosed with
TNBC, as previously reported (Jack et al. 2013). This diag-
nosis was more likely in younger women, those living in
more deprived areas, and with a more advanced stage of
disease (Jack et al. 2013).
Pal et al. SpringerPlus 2014, 3:553 Page 3 of 5
http://www.springerplus.com/content/3/1/553Table 1 shows the numbers and percentages of patients
that received each type of treatment within the first six
months after diagnosis, as well as the odds ratios (OR) of
patients with TNBC receiving each type of treatment com-
pared to patients without TNBC. Adjustment for age,
stage and socioeconomic deprivation attenuated the asso-
ciations somewhat. The likelihood of patients with TNBC
receiving surgery was similar to that of patients without
TNBC (adjusted OR = 1.05, 95% confidence interval (CI):
0.68-1.62). Patients with TNBC were more likely to receive
chemotherapy (adjusted OR = 4.21, 95% CI: 2.63-6.75) and
a combination of surgery plus chemotherapy (adjusted
OR= 2.52, 95% CI: 1.61-3.93) than patients without
TNBC. Those with TNBC appeared to be less likely to re-
ceive radiotherapy (adjusted OR = 0.71, 95% CI: 0.42-1.19).
The 5-year survival rates according to TNBC status
and treatment received are shown in Table 2. Patients
with TNBC had significantly lower 5-year survival [0.62
(95% CI: 0.53-0.69)] than patients without TNBC [0.75
(95% CI: 0.72-0.78)]. The highest 5-year survival rates
were observed for patients without TNBC who received
surgery (0.86 95% CI: 0.84-0.89), surgery and chemother-
apy (0.86, 95% CI: 0.80-0.90) and radiotherapy (0.87,
95% CI: 0.82-0.91). Among patients with TNBC however,
the highest 5-year survival was observed following a com-
bination of surgery and chemotherapy (0.74, 95% CI: 0.60-
0.83). Patients with TNBC who received radiotherapy had
a much lower 5-year survival of 0.30 (95% CI: 0.12-0.50).
Due to the small numbers of patients with TNBC receiv-
ing hormone therapy (3) or no treatment (14), these data
are not shown.
Hazard ratios (HR) for patients who were diagnosed
with TNBC compared with a baseline of patients without
TNBC are shown in Table 3. Patients with TNBC had a
higher risk of death compared with patients without TNBC
(HR= 1.61, 95% CI 1.20-2.17). Adjustments for age, stage
of disease and socioeconomic deprivation increased the
hazard ratio to 1.84 (95% CI 1.36-2.49). Further adjust-
ment for treatment attenuated this hazard ratio slightly,
but it was still significantly higher in patients with TNBCTable 1 Odds ratios (OR) and 95% confidence intervals (CI) of r
cancer patients with TNBC (TNBC), and without TNBC (non-TNB
Number and % of patients receiving treatme
TNBC Non-TNBC
N (%) n (%)
Treatment
Surgery 86 (67) 747 (68)
Chemotherapy 80 (63) 293 (27)
Surgery & chemotherapy 53 (41) 208 (19)
Radiotherapy 20 (16) 249 (23)
Hormone therapy 3 (2) 433 (39)compared with patients without TNBC (HR 1.69, 95% CI
1.24-2.30).
Discussion
This study of a London population found that women
with TNBC were more likely to receive chemotherapy, or
a combination of surgery and chemotherapy within six
months of diagnosis, compared with patients without
TNBC. Five-year survival amongst patients with TNBC
was observed to be greatest following surgery and chemo-
therapy combined, but despite this, patients with TNBC
had a poorer overall survival than those without.
Our analysis found that 63% and 41% of patients with
TNBC, received chemotherapy and combination therapy,
respectively. There are no previous population-based stud-
ies in the UK so comparison of the treatment of this popu-
lation of patients with TNBC with others is difficult.
However these findings are consistent with evidence-
based treatment recommendations (Isakoff 2010; Rodler
et al. 2010; Carey et al. 2010). This study also found that
16% of patients with TNBC received radiotherapy. NICE
guidelines for the use of radiotherapy in breast cancer
are not specific to TNBC, and state that radiotherapy
should be offered in early and locally invasive breast
cancer, or where the risk of disease recurrence is high
(National Institute for Health and Care Excellence
2010). Therefore treatment with radiotherapy in this co-
hort may have been determined by the size and spread
of triple negative tumours. Interestingly, a recent study
has reported that radiotherapy following mastectomy is
associated with improved prognosis (Chen et al. 2013),
though this has yet to be incorporated into clinical
guidelines for TNBC treatment. Patients with TNBC
do not usually benefit from hormone therapies such as
anti-HER2 or endocrine-directed treatment which are
known to be effective in other kinds of breast cancer
(Macmillan Cancer Support). Thus, the finding that
these patients were much less likely to receive hor-
mone therapy compared to other treatments is likely to
reflect good clinical practice.eceiving each type of treatment comparing female breast
C) (North East London Cancer Network, 2005 – 2007)
nt
Unadjusted Adjusted for age, stage and
socioeconomic deprivation
OR (95% CI) p OR (95% CI) p
0.97 (0.66, 1.43) 0.869 1.05 (0.68, 1.62) 0.815
4.59 (3.13, 6.73) <0.001 4.21 (2.63, 6.75) <0.001
3.03 (2.07, 4.44) <0.001 2.52 (1.61, 3.93) <0.001
0.63 (0.38, 1.04) 0.072 0.71 (0.42, 1.19) 0.194
0.04 (0.01, 0.12) <0.001 0.04 (0.01, 0.12) <0.001
Table 2 Five-year survival estimates and 95% confidence
intervals (CI) of patients with TNBC (TNBC) and without








Overall 0.62 (0.53, 0.69) 0.75 (0.72, 0.78)
Treatment
received:
Surgery 0.65 (0.54, 0.74) 0.86 (0.84, 0.89)
Chemotherapy 0.65 (0.53, 0.74) 0.77 (0.71, 0.81)
Surgery plus
chemotherapy
0.74 (0.60, 0.83) 0.86 (0.80, 0.90)
Radiotherapy 0.30 (0.12, 0.50) 0.87 (0.82, 0.91)
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patients with TNBC who received chemotherapy, and
best following surgery plus chemotherapy, compared
with other treatments. This may be partly due to previ-
ously reported favourable responses to chemotherapy in
TNBC. However, patients with a better prognosis may
also have been more likely to have been selected into re-
ceiving more aggressive treatment, and this should be
taken into consideration when interpreting the survival
results. This study also found that the 5-year overall sur-
vival rate for patients with TNBC was 62%, compared to
75% in patients without TNBC. This is comparable with
several publications which have reported an overall 5-
year survival of between 59-77% in patients with triple
negative disease (Schwentner et al. 2012; Ovcaricek et al.
2011; Chu et al. 2012; Dent et al. 2007). Our findings also
corroborate the previously reported poorer prognosis of
patients with TNBC compared with patients without
TNBC (Liedtke et al. 2008; Schwentner et al. 2012;
Ovcaricek et al. 2011; Wu et al. 2011), even after adjusting
for possible confounding factors (Wu et al. 2011;
Schwentner et al. 2012; Von Minckwitz & Martin 2012).
Of interest are those studies which have reported similarTable 3 Hazard ratios (HR) and 95% confidence intervals
(CI) and p values according to TNBC status and
sequentially adjusted for age, stage, socioeconomic
deprivation and treatment
HR 95% CI p
Non-TNBC 1.00
TNBC 1.61 1.20, 2.17 0.002
TNBC (age-adjusted) 2.01 1.49, 2.72 <0.001
TNBC (age, stage, socioeconomic
deprivation adjusted)
1.84 1.36, 2.49 <0.001
TNBC (age, stage, socioeconomic
deprivation and treatment adjusted)
1.69 1.24, 2.30 0.001survival of patients with and without TNBC when a
complete response of no invasive or in situ residuals in the
breast and nodes) can be confirmed by pathology
(Schwentner et al. 2012; Wang et al. 2009).
In future studies, it would be important to explore fur-
ther the treatment and survival of patients with TNBC
in other areas of London, and on a national level to in-
vestigate treatment patterns and survival across the UK.
A larger population of patients with TNBC would also
provide more representative results, particularly if more
complete data on triple negative status can be obtained.
National and local audit of current clinical practice for
the treatment offered to and received by patients with
TNBC may also represent a profitable area of investiga-
tion, as shown previously in Germany (Schwentner et al.
2012). Our study has some limitations. First, a significant
proportion of women included in the study had an un-
known hormone receptor status due to incomplete path-
ology data. This may represent the reality of
documentation and reporting of disease for large popu-
lations in the National Health Service. Ideally, more ac-
curate and improved pathology reporting would enable
triple negative disease status to be determined for a
greater proportion of patients. Pathology records are now
being routinely received by the National Cancer Registra-
tion Service and data on triple negative status are now in-
cluded within registration records. Future studies will
therefore be able to make use of larger and more complete
samples. Second, treatment data were available for up to
six months (183 days) from diagnosis only, which captures
the primary treatment received. Again further treatments
are now being recorded in registration data, opening up
the possibility of studying them and their possible associ-
ation with survival as well as treatment at recurrence.
Third, data on co-morbidities were not included and this
may have affected either the treatment that women re-
ceived, or their prognosis following treatment. Future
studies can make use of co-morbidity data now available
within cancer registration data from linked Hospital Epi-
sode Statistics data on other admissions.
Triple negative disease of the breast is well reported to
be an aggressive subtype of breast cancer. This study of
a large London population observed that patients with
TNBC have poorer overall survival compared to patients
without TNBC. However, it is reassuring to find that in
line with evidence-based guidelines, women diagnosed
with TNBC were more likely to receive chemotherapy
or a combination of surgery and chemotherapy, com-
pared to patients without TNBC. This suggests that fur-
ther population-based studies have potential, along with
clinical studies, to contribute to understanding and im-
proving survival for these women.
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